Critical Review: Qualigen Therapeutics (NASDAQ:QLGN) & Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics (NASDAQ:SLNO) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Earnings & Valuation

This table compares Soleno Therapeutics and Qualigen Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$190.40 million	8.89	$20.89 million	$0.23	142.61
Qualigen Therapeutics	N/A	N/A	-$6.26 million	($7.50)	-0.19

Soleno Therapeutics has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Soleno Therapeutics has a beta of -3.16, meaning that its share price is 416% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Profitability

This table compares Soleno Therapeutics and Qualigen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	N/A	5.90%	4.61%
Qualigen Therapeutics	N/A	N/A	-202.16%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Soleno Therapeutics and Qualigen Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	1	1	12	1	2.87
Qualigen Therapeutics	1	0	0	0	1.00

Soleno Therapeutics currently has a consensus price target of $104.54, suggesting a potential upside of 218.71%. Given Soleno Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Qualigen Therapeutics.

Summary

Soleno Therapeutics beats Qualigen Therapeutics on 12 of the 13 factors compared between the two stocks.

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.